More headlines and perspectivesbiotech
NervGen Wins FDA Breakthrough Therapy Designation for Spinal Cord Injury Drug as Phase 3 Enrollment Advances
2 articles · 2 sources · updated 10 days agoRecent
Manila TimesNervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury10 days ago · By GlobeNewswire0
